Can-Fite BioPharma Ltd.
CANF | AMEX
$2.22
-$0.02 (-0.89%)
At close: Sep 21, 2026, 4:00 PM ET
$2.26
+$0.04 (+1.74%)
Pre-market:
Sep 22, 2026, 4:44 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 408.21K | 674K | 743K | 810K | 853K | 763K |
Cost of Revenue | 24.19K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 384.02K | 674K | 743K | 810K | 853K | 763K |
Operating Income | -10.03M | -8.13M | -8.2M | -10.1M | -12.84M | -14.14M |
Interest Income | 286.25K | 291K | 506K | 222K | 24K | 44K |
Pretax Income | -9.91M | -7.88M | -7.63M | -10.17M | -12.62M | -14.44M |
Net Income | -9.91M | -7.88M | -7.63M | -10.17M | -12.6M | -14.44M |
Selling & General & Admin | 3.67M | 3.05M | 2.96M | 3.14M | 3.85M | 2.95M |
Research & Development | 6.75M | 5.76M | 5.98M | 7.76M | 9.85M | 11.95M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 10.41M | 8.8M | 8.94M | 10.91M | 13.7M | 14.9M |
Interest Expense | 14.11K | 14K | 14K | 77K | 18K | 363K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.44M | 8.8M | 8.94M | 10.91M | 13.7M | 14.9M |
Income Tax Expense | n/a | n/a | n/a | 360K | -20K | n/a |
Shares Outstanding (Basic) | 823.93K | 7.25M | 4.26M | 2.72M | 1.53M | 1.14M |
Shares Outstanding (Diluted) | 823.93K | 7.25M | 4.26M | 2.72M | 1.84M | 1.19M |
EPS (Basic) | -12.03 | -1.08 | -1.80 | -3.75 | -9 | -12.69 |
EPS (Diluted) | -12.03 | -1.08 | -1.80 | -3.75 | -8.25 | -12.69 |
EBITDA | -10M | -8.12M | -8.18M | -10.08M | -12.83M | -14.13M |
EBIT | -10.03M | -8.13M | -8.2M | -10.1M | -12.84M | -14.14M |
Depreciation & Amortization | 24.19K | 7K | 15K | 14K | 14K | 12K |
Add to Watchlist
Select watchlists to add or remove CANF